Jeffrey M. Holzbeierlein, MD, FACS

Professor and John W Weigel Interim Chair
Director of Urologic Oncology

Specialist in:

  • Urologic Cancer Surgery
  • Robotic Minimally Invasive Urologic Surgery
  • Prostate Cancer Research

Dr. Jeffrey Holzbeierlein is the Professor and John W. Weigel Interim Chair, and the Director of Urologic Oncology at the University of Kansas Medical Center. He was raised in Edmond, Oklahoma and received his medical degree from the University of Oklahoma. He joined the faculty at KU after completing his internship and residency at Vanderbilt University and a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York.. He specializes in urological cancer surgery especially bladder, kidney, penile and testicular cancer and has the largest experience and volume in bladder cancer surgery reconstruction in the region and well respected by the community.

Dr. Holzbeierlein is a member of the Society of Urologic Oncology (SUO) where he is the Fellowship Director and serves on the Executive Board of the SUO. He is the Secretary of the South Central Section of the American Urological Association and serves on the Board of Directors and is also on the Nominating Committee. He is on the American Board of Urology Examination Committee and is an Assistant Editor for the Journal of Urology. In addition, he is a Fellow of the American College of Surgeons and serves on the Kansas selection board. Dr. Holzbeierlein is also the past Chair of the Young Urologic Oncologists Section of the Society of Urologic Oncology. He is a reviewer for the Journal of Urology, Practical Reviews in Urology, Cancer, and Urologic Oncology. He was recently awarded the Resident Mentoring Award for faculty at the University of Kansas Hospital. He was voted as one of the best urologists in Kansas City by the KC Business Journal in 2011 as well as one of the best urologist in the Kansas City region by U S News and World Reports for 2011-2012

Dr. Holzbeierlein serves on numerous hospital committees including the the University of Kansas Physicians Board of Directors, the Compliance Committee, the Elections Committee for the School of Medicine, and the Board for the Kansas Tissue and Serum Repository. He is also co-director of the K-Inbre core.

 Dr. Holzbeierlein has published numerous peer reviewed journal articles, numerous presentation and abstracts in journals and textbooks dealing with urologic oncology. He has previous grant support including a Department of Defense New Investigator Award and was a co-investigator on an R01.

His research interest includes the androgen receptor as a target of Hsp90 inhibitors in prostate cancer and clinically decreasing the morbidity associated with cystectomy. He lives in Kansas City with his wife Jill and their 4 children.

Question and Answer with Dr. Holzbeierlein

Last modified: Aug 18, 2016

Jeffrey Maxwell Holzbeierlein, MD, FACS


Jeffrey M. Holzbeierlein, MD, FACS
Professor and John W Weigel Interim Chair
Director of Urologic Oncology